TheraScreen: EGFR29 is the first CE marked diagnostic kit for EGFR mutation detection. It is used to aid doctors in selecting lung cancer patients suitable for treatment with tyrosine kinase inhibitor therapies.

The K-RAS Mutation Test Kit has now been CE-Marked and will be available for professional diagnostic use from 1st January 2008. We have completed the EU registration and the product is CE-marked under the European IVD Directive 98/79/EC. The kit detects seven key mutations in codons 12 and 13 of the K-RAS oncogene. More information to follow.